Novo Nordisk A/S is a leading pharmaceutical company that embodies values of integrity, innovation, and accountability. With a strong focus on improving the lives of patients, Novo Nordisk is committed to sustainable healthcare and pioneering treatments for diabetes and other chronic conditions. The company's corporate philosophy revolves around patient-centricity, scientific excellence, and ethical business practices. Novo Nordisk aims to create long-term value for stakeholders while ensuring accessibility and affordability of its life-saving therapies. Through extensive research and development, Novo Nordisk continuously strives to deliver innovative solutions that positively impact global health.

Novo Nordisk A/S is primarily present in countries and regions worldwide. As a leading global pharmaceutical company specializing in diabetes care, Novo Nordisk operates in more than 170 countries. Its presence extends across North America, Europe, Asia, Africa, and South America. With its headquarters situated in Denmark, Novo Nordisk has a strong presence in its home country. The company's expansive reach allows it to provide innovative diabetes treatments and other healthcare solutions to a diverse range of individuals and communities globally.

Novo Nordisk A/S, a leading global pharmaceutical company, has achieved significant milestones throughout its history. Notably, Novo Nordisk introduced the world's first insulin for diabetes treatment in 1923. Over the years, the company has consistently pioneered innovative medicines and devices for diabetes and other serious chronic conditions such as obesity, hemophilia, and growth disorders. Novo Nordisk's commitment to research and development has led to numerous breakthroughs in insulin therapies, including the launch of long-acting insulin analogs and the first concentrated insulin for diabetes patients. Furthermore, the company has expanded its global presence, ensuring access to life-saving medications in more than 170 countries. Novo Nordisk's relentless pursuit of improving patient care has established it as a trusted leader in the healthcare industry.

Novo Nordisk A/S is a renowned pharmaceutical company founded in 1923 in Denmark. With a strong commitment to improving the lives of people with diabetes and other chronic diseases, Novo Nordisk has become a global leader in the field. Over the years, the company has built a rich history of innovation, developing groundbreaking insulin and other therapeutic solutions. Novo Nordisk has expanded its portfolio to include products for obesity, rare bleeding disorders, and growth hormone deficiencies. With its dedication to research and development, Novo Nordisk continues to strive for better treatment options, making a significant impact on patients worldwide.

The main competitors of Novo Nordisk A/S in the market are Eli Lilly and Company, Sanofi S.A., and Johnson & Johnson.

Novo Nordisk A/S is primarily active in the pharmaceutical industry, specifically focused on diabetes care. With a strong emphasis on research, development, and production of diabetes medication and innovative treatment solutions, Novo Nordisk leads the way in delivering effective therapies for managing diabetes. The company also engages in the production of other biopharmaceuticals, such as hemophilia treatments, growth disorders, and obesity therapies. Novo Nordisk excels in providing comprehensive healthcare solutions within the field of endocrinology, catering to the needs of patients worldwide.

Novo Nordisk A/S is a renowned global pharmaceutical company specializing in the production and distribution of diabetes care products. The business model of Novo Nordisk is centered around developing innovative and effective treatments for diabetes and other serious chronic diseases. With a strong focus on research and development, Novo Nordisk aims to provide accessible and high-quality healthcare solutions to improve the lives of people worldwide. Through strategic partnerships, extensive market presence, and continuous product advancements, Novo Nordisk strives to address the growing global health challenges while maintaining sustainable business growth.

Novo Nordisk A/S의 P/E 비율은 46.3입니다.

Novo Nordisk A/S의 P/S 비율은 12.24입니다.

Novo Nordisk A/S에 대한 AlleAktien 품질 점수는 10/10입니다.

예상되는 Novo Nordisk A/S 매출은 293.18 조. DKK입니다.

예상되는 Novo Nordisk A/S 이익은 77.49 조. DKK입니다.

Novo Nordisk A/S is a Danish company specializing in the development and production of diabetes medications. It operates globally and offers products and services in over 170 countries. The company has three business areas: Diabetes and Obesity, Biopharmaceuticals, and Hemophilia. The Diabetes and Obesity business area is the core of its business model, offering insulin products, GLP-1 analogs, and other medications for diabetes and obesity treatment. Novo Nordisk also provides digital solutions for patient management and self-care. The Biopharmaceuticals business area focuses on developing medications for inflammatory diseases, metabolic disorders, and other critical conditions. The Hemophilia business area includes factor replacement therapies for the treatment of hemophilia and other bleeding disorders. Novo Nordisk complements its business model with research and development initiatives to optimize existing products and develop new ones. The company has global research centers and production sites in Denmark, China, Brazil, and the United States. It also engages in partnerships and collaborations to accelerate the development and production of diabetes products and other medications. Overall, Novo Nordisk's business model offers an integrated solution to improve the health and well-being of diabetes patients worldwide, combining innovative technology and traditional treatment approaches to meet the needs of patients, doctors, and healthcare systems.

Novo Nordisk A/S은(는) 연간 2번의 배당을 통해 11.15 DKK의 배당금을 지급합니다.

Novo Nordisk A/S는 연간 2번의 배당금을 지급합니다.

Novo Nordisk A/S의 ISIN은 DK0060534915입니다.

Novo Nordisk A/S의 WKN은 A1XA8R입니다.

Novo Nordisk A/S의 티커는 NOVO B.CO입니다.

지난 12개월 동안 Novo Nordisk A/S은(는) 14.15 DKK 의 배당금을 지급했습니다. 이는 약 1.77 %의 배당 수익률에 해당합니다. 향후 12개월 동안 Novo Nordisk A/S은(는) 14.94 DKK의 배당금을 지급할 것으로 예상됩니다.

Novo Nordisk A/S의 현재 배당 수익률은 1.77 %입니다.

Novo Nordisk A/S은 분기별로 배당금을 지급합니다. 이는 , , , 월에 배당됩니다.

Novo Nordisk A/S은(는) 지난 26년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 14.94 DKK의 배당금이 예상됩니다. 이는 배당수익률 1.87 %에 해당합니다.

Novo Nordisk A/S은 '건강' 섹터에 속합니다.

Novo Nordisk A/S의 마지막 배당금을 0.51 DKK만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Novo Nordisk A/S는 11.15 DKK를 배당금으로 지급했습니다.

Novo Nordisk A/S의 배당금은 DKK에 지급됩니다.